LIXTE.jpg
Inactivating Mutations in Scaffold Component of PP2A, the Target Enzyme of LIXTE Biotechnology’s Clinical Compound LB-100, are Associated with Exceptionally Long Survival of Patients with Ovarian Clear Cell Cancer Treated with Immunotherapy
March 22, 2022 08:30 ET | Lixte Biotechnology Holdings, Inc.
Outside research reports that immune checkpoint therapy of patients with ovarian clear cell carcinomas with mutations reducing PP2A activity in their cancers (loss-of-function mutations) correlates...
Jessica Stine, MD
FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE GYNECOLOGIC ONCOLOGIST JESSICA STINE, MD NAMED NATIONAL GYNECOLOGIC ONCOLOGY OBSERVATION SITE
November 03, 2021 09:30 ET | Florida Cancer Specialists & Research Institute
Tampa, Fla., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Jessica Stine, MD, gynecologic oncologist with Florida Cancer Specialists & Research Institute (FCS), and an advanced robotic surgeon who performs...
Florida Cancer Specialists & Research Institute Celebrates Opening of New Cancer Center in Tallahassee
April 29, 2021 08:28 ET | Florida Cancer Specialists
Fort Myers, Fla., April 29, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) physicians and senior leaders gathered this week for a ribbon-cutting ceremony to...
Logo.jpg
Poster on Celsion Corporation’s Phase I/II OVATION 2 Study Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer
April 01, 2021 08:30 ET | Celsion CORP
Company reports further strengthening of R0 resection results in patients treated with GEN-1 LAWRENCEVILLE, N.J., April 01, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a...
Logo.jpg
Poster on Celsion Corporation’s Phase I/II OVATION 2 Study to be Presented at the Society of Gynecologic Oncology Virtual Annual Meeting on Women’s Cancer
March 02, 2021 08:45 ET | Celsion CORP
LAWRENCEVILLE, N.J., March 02, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
22157.jpg
Global Gynecology Partnering Deal Trends, Players and Financials Directory 2010-2020
December 11, 2020 09:33 ET | Research and Markets
Dublin, Dec. 11, 2020 (GLOBE NEWSWIRE) -- The "Global Gynecology Partnering 2010-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering. Global...
22157.jpg
Global Gynecology Partnering Deal Trends, Players and Financials Directory 2010-2020
September 24, 2020 04:49 ET | Research and Markets
Dublin, Sept. 24, 2020 (GLOBE NEWSWIRE) -- The "Global Gynecology Partnering 2010-2020: Deal trends, players and financials" report has been added to ResearchAndMarkets.com's offering. Global...
Margarett C. Ellison, MD of Gynecologic Oncology of Tallahassee Joins Florida Cancer Specialists & Research Institute
April 15, 2020 09:17 ET | Florida Cancer Specialists
Tallahassee, Fla., April 15, 2020 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) is pleased to announce the addition of gynecologic-oncologist Dr. Margarett C. Ellison...
Logo.jpg
Celsion Announces Publication of Results of National Institutes of Health (NIH) Analysis of ThermoDox® in Journal of Vascular and Interventional Radiology
August 13, 2019 08:00 ET | Celsion CORP
NIH’s Independent Analysis of Celsion’s Phase III HEAT Study Confirms Increasing Radiofrequency Ablation (RFA) Heating Time + ThermoDox® Improves Overall Survival with Significance in Patients with...
Logo.jpg
Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities
August 09, 2019 08:30 ET | Celsion CORP
Presentation Slides Available on Celsion’s Website LAWRENCEVILLE, N.J, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that...